Speeding The Drug Development Process Through The Use Of High Yield, Stable Gpex® Technology


Presentation by Catalent Expert at Cell Culture World Congress

Somerset, NJ, February 26, 2013 – Dr. Greg Bleck, R&D Platform Director-Biologics, Catalent Pharma Solutions, is to present “GPEx Cell Line Engineering: Higher Yields and Greater Stability, Case Studies using Multiple Mammalian Cell Lines” at the third annual Cell Culture World Congress on February 26, 2013. Dr. Bleck’s presentation, will give attendees an understanding of how Catalent’s GPEx Technology with Cell Line Engineering was incorporated into several cell line expression / product development projects. The challenges of the overall projects, the procedures completed, analysis of the data produced, insights gained and final conclusions reached will demonstrate how GPEx technology was used to generate mammalian cells with high yields and greater stability, helping to speed the drug development process.

Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics. He has a broad background in molecular biology, mammalian gene expression, cell culture and transgenic animals. Dr. Bleck holds a Bachelor’s degree in Dairy Science and has a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison.  He performed postdoctoral work at the University of Illinois-Urbana, working in the areas of gene regulation and expression. Dr. Bleck has published more than 55 research papers and co-authored three book chapters.

The Cell Culture World Congress takes place from February 26 – 28, 2013. Dr. Bleck’s presentation is scheduled at 15.10 in Nymphenberg rooms 1 & 2 at the Hotel Sofitel Munich Bayerpost, Munich, Germany.

For further information and to register, please visit http://www.terrapinn.com/2013/cellculture/index.stm

To schedule an interview with Dr. Bleck, please contact Chris Halling at chris.halling@catalent.com .

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com .

more products. better treatments. reliably supplied.™